CYP17A1 and hypertensive disorder: According to the manufacturer package insert regarding warnings and precautions, hypertension as well as hypokalemia and fluid retention may be caused by abiraterone as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition.